表紙
市場調查報告書
商品編碼
1032894

肺部藥物輸送系統市場:2021年∼2026年的預測

Pulmonary Drug Delivery Systems Market - Forecasts from 2021 to 2026

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

肺部藥物輸送系統的市場規模,2019年是409億2900萬美金。該市場,預計在今後以4.83%的年複合成長率擴大,2026年達到569億4200萬美元。全球慢性呼吸疾病罹患率高漲,帶動在預測期間內的肺部藥物輸送系統市場成長。根據世界衛生組織,10億人以上罹患急性或慢性呼吸疾病。還有約400萬人死於慢性呼吸道疾病。還有在世界約有2億3,500萬人罹患患氣喘病,氣喘的死亡中80%以上在低、中所得國發生。由於這樣的疾病的發生率提高,和需要治療肺部藥物輸送系統的患者增加,市場預計成長。

本報告提供肺部藥物輸送系統市場相關調查,市場概要,以及各產品,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場促進因素
  • 市場阻礙因素
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入企業的威脅
    • 替代品的威脅
    • 功能的競爭企業的關係
  • 產業的價值鏈分析

第5章 肺部藥物輸送系統市場分析,各產品

  • 簡介
  • 定量吸入器(MDI)
  • 乾粉吸入劑(DPI)
  • 緩霧吸入器(SMI)
  • 噴霧器

第6章 肺部藥物輸送系統市場分析,各流通管道

  • 簡介
  • 離線
  • 線上

第7章 肺部藥物輸送系統市場分析,各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 中東、非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 印尼
    • 台灣
    • 泰國
    • 其他

第8章 競爭資訊

  • 競爭基準與分析
  • 最近的投資和交易
  • 主要參與者的策略

第9章 企業簡介

  • Philips Respironics
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • 3M Healthcare
  • PARI GmbH
  • F. Hoffmann-La Roche AG
  • Gilbert Technologies
  • AstraZeneca PLC
目錄
Product Code: KSI061611953

The pulmonary drug delivery systems market is projected to grow at a CAGR of 4.83% to reach US$56.942 billion by 2026, from US$40.929 billion in 2019. The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.

Increasing geriatric population

Moreover, the rapidly growing geriatric population worldwide will contribute to the market growth as they are more prone to chronic respiratory diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease, etc. which will surge the demand for pulmonary drug delivery systems in the market. According to the United Nations, in 2019, the geriatric population was 703 million persons, nationwide. The number of older persons is projected to double to 1.5 billion in 2050.

Health awareness

Furthermore, the growing health awareness and increasing investment in the healthcare and drug delivery industry by both public and private players are also expected to further fuel up the growth of the market. Also, the initiative taken by the governing bodies of various countries is increasing health awareness among the people. For instance, the National Asthma Control Program (NACP) by CDS, provides funds for educating asthma-affected patients. Such initiatives will encourage more patients to adopt pulmonary drug delivery systems for their treatment which will further strengthen the market growth during the forecast period.

Market Segmentation

By product, the dry powder inhalers (DPIs) segment is projected to hold a significant market share owing to the advantages such as short administration & preparation time, ease of use, and fewer irritant effects associated with the use of these inhalers. Geographically, North America holds a significant market share due to the increasing prevalence of chronic respiratory diseases, early adoption of the pulmonary drug delivery systems, and the surge in healthcare spending in the region. Asia Pacific will be the fastest-growing market region owing to the rapidly growing geriatric population, increasing adoption of an unhealthy lifestyle, and rising urbanization in the region.

Growth Factors

Increase in the geriatric population

The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems. According to COPD, about 1 in 7 older adults suffers from some of the other forms of lung disease. The geriatric population is more prone to chronic respiratory diseases as compared to the younger population which will increase the demand for pulmonary drug delivery systems in the market during the forecast period.

Restraints

Lack of awareness

The pulmonary drug delivery system is a relatively new system due to which not many patients are aware of the advantages of using this system which may restrain the market growth during the forecast period. The patients, especially in the developing countries are unaware of the existence of this system due to which the demand for it is low in these countries. However, with the increasing awareness by both the public and private players the patients are expected to become aware and adopt these systems.

Impact of COVID-19 on the pulmonary drug delivery systems market

The Covid-19 pandemic positively impacted the pulmonary drug delivery systems market as the novel coronavirus directly or indirectly attacks the respiratory system of the patient. There was a rapid spike in the number of patients suffering from respiratory diseases as the potent virus made their lungs weak, which, in turn, increased the demand for pulmonary drug delivery systems, worldwide. The virus outbreak continues to linger in many countries even after a year which is expected to further drive the market growth during the forecast period.

Competitive Insights

The market leaders for the pulmonary drug delivery systems market consist of Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, and AstraZeneca PLC. The key players in the market implement growth strategies such as product launches, mergers, and acquisitions, etc. to gain a competitive advantage over their competitors.

Segmentation

By Product

  • Metered-dose inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Soft mist inhaler (SMI)
  • Nebulizers

By Distribution Channel

  • Offline
  • Online

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Pulmonary Drug Delivery Systems Market Analysis, By Product

  • 5.1. Introduction
  • 5.2. Metered-dose inhalers (MDIs)
  • 5.3. Dry Powder Inhalers (DPIs)
  • 5.4. Soft mist inhaler (SMI)
  • 5.5. Nebulizers

6. Pulmonary Drug Delivery Systems Market Analysis, By Distribution Channel

  • 6.1. Introduction
  • 6.2. Offline
  • 6.3. Online

7. Pulmonary Drug Delivery Systems Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
    • 7.2.4. Others
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Others

8. Competitive Intelligence

  • 8.1. Competitive Benchmarking and Analysis
  • 8.2. Recent Investment and Deals
  • 8.3. Strategies of Key Players

9. Company Profiles

  • 9.1. Philips Respironics
  • 9.2. GlaxoSmithKline PLC
  • 9.3. Boehringer Ingelheim GmbH
  • 9.4. Teva Pharmaceutical Industries Ltd.
  • 9.5. 3M Healthcare
  • 9.6. PARI GmbH
  • 9.7. F. Hoffmann-La Roche AG
  • 9.8. Gilbert Technologies
  • 9.9. AstraZeneca PLC